Albiglutide Fragment (GLP-1 fragment 7-36) TFA, the trifluoroacetic acid form of albiglutide fragment, is one copy of the 30-amino-acid sequence of modified human glucagon-like peptide-1 (GLP-1, fragment 7-36). Albiglutide Fragment does not contain the albumin section, which could be foud in the full sequence of albiglutide (trade names Eperzan; Tanzeum; GSK-716155; GSK716155; albugon), a long-acting GLP-1 agonist approved for the treatment of type 2 diabetes mellitus (T2DM). It was developed and marketed as an anti-diabetic/anti-hyperglycemic drug by GlaxoSmithKline (GSK) in EU and US under the trade names of Eperzan and Tanzeum, respectively.

纯度：≥98%